Multicentre double blind placebo controlled parallel group dose ranging study of ATL-962 [cetilistat] to assess weight loss, safety and tolerability in obese patients with type II diabetes being treated with metformin, in comparison with orlistat

Trial Profile

Multicentre double blind placebo controlled parallel group dose ranging study of ATL-962 [cetilistat] to assess weight loss, safety and tolerability in obese patients with type II diabetes being treated with metformin, in comparison with orlistat

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Cetilistat; Orlistat
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2007 Results presented at the 15th European Congress on Obesity (ECO 2007).
    • 28 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top